This is simply my take...
Ultimately money can overcome almost any obstacle, but Hepalink's position, and to a certain extent that of Eastern (they're around 20% I believe)...I think it complicates issues, plus you have Royalty Preferred Shares held by Zenith. I believe it would make Resverlogix and/or just Apabetalone a very convoluted acquisition.
It should be noted, in case you're not aware...Eastern Capital, that's actually Kenneth Dart of the Dart Container fortune, he has a net worth estimated at over $6 billion. Eastern is simply his investment company.
I've long considered the most likely deal to be one where Shenzhen Hepalink takes Resverlogix over and maybe even uses an acquisition as an entry to the North American capital markets. Still, even while I think its 'most likely' I also see the share structure and ownership situation to be more than a little problematic, but just a bit less so if Hepa was doing the acquiring.
News 
Market Data 
Discover 
AI
